Abbvie's CD3 and CD20 dual antibody Aikuiruituo monoclonal antibody has been submitted for listing in China
On November 6th, the CDE website showed that Abbvie's CD3/CD20 bispecific antibody epcoritamab (U.S. trade name: Epkinly) has been submitted for market approval in China. Epcoritamab is an IgG1 bispecific antibody developed by Genmab using its proprietary DuoBody technology, which can simultaneously target CD3 on T cells and CD20 on B cells, inducing T cell-mediated killing of CD20+ cells. In June 2020, Abbvie and Genmab reached an agreement to jointly develop and commercialize three bispecific antibodies, including this product. The mechanism of action of epcoritamab (source: Abbvie official website) In the EPCORE NHL-1 study, DLBCL patients (n=148) treated with epcoritamab had an overall response rate (ORR) of 61%, a complete response rate (CR) of 38%, and a median duration of response (mDOR) of 15.6 months; FL patients (n=128) treated with epcoritamab had an ORR of 82%, with mDOR not yet reached, and 68.4% of patients achieved a DOR of 12 months
According to the Zhitong Finance APP, on November 6th, the CDE website showed that Abbvie (ABBV.US) has applied for the listing of its CD3/CD20 dual antibody epcoritamab (US trade name: Epkinly) in China.
Epcoritamab is an IgG1 bispecific antibody developed by Genmab using its proprietary DuoBody technology, which can simultaneously target CD3 on T cells and CD20 on B cells, inducing T cell-mediated killing of CD20+ cells. In June 2020, Abbvie and Genmab reached an agreement to jointly develop and commercialize three bispecific antibodies, including this product.
Mechanism of action of Epcoritamab (Source: Abbvie official website)
In the EPCORE NHL-1 study, DLBCL patients (n=148) treated with Epcoritamab had an overall response rate (ORR) of 61%, a complete response rate (CR) of 38%, and a median duration of response (mDOR) of 15.6 months; FL patients (n=128) treated with Epcoritamab had an ORR of 82%, with mDOR not yet reached, and 68.4% of patients had a DOR of 12 months
